Cover Image
市場調查報告書

原發性經痛:開發中產品分析

Primary Dysmenorrhea - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 199781
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
原發性經痛:開發中產品分析 Primary Dysmenorrhea - Pipeline Review, H2 2014
出版日期: 2014年07月31日 內容資訊: 英文 37 Pages
簡介

所謂原發性經痛是指月經時發生的復發性、痙攣性下腹部疼痛,是青年期女性最常見的婦女病。主要的症狀有噁心嘔吐、下痢、虛浮感、或是全身痛。

本報告提供原發性經痛的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,再加上主要企業簡介,藥物簡介,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

原發性經痛概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

治療藥的開發企業

  • Merck & Co., Inc.
  • PDC Biotech GmbH
  • Jiangsu Kanion Pharmaceutical Co., Ltd

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介(產品說明·作用機制·R&D進展)

開發中產品的最新趨勢

暫停的計劃

中止的計劃

最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5297IDB

Summary

Global Markets Direct's, 'Primary Dysmenorrhea - Pipeline Review, H2 2014', provides an overview of the Primary Dysmenorrhea's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Primary Dysmenorrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Primary Dysmenorrhea and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Primary Dysmenorrhea
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Primary Dysmenorrhea and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Primary Dysmenorrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Primary Dysmenorrhea pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Primary Dysmenorrhea
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Primary Dysmenorrhea pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Primary Dysmenorrhea Overview
  • Therapeutics Development
    • Pipeline Products for Primary Dysmenorrhea - Overview
    • Pipeline Products for Primary Dysmenorrhea - Comparative Analysis
  • Primary Dysmenorrhea - Therapeutics under Development by Companies
  • Primary Dysmenorrhea - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Primary Dysmenorrhea - Products under Development by Companies
  • Primary Dysmenorrhea - Companies Involved in Therapeutics Development
    • Merck & Co., Inc.
    • PDC Biotech GmbH
    • Jiangsu Kanion Pharmaceutical Co., Ltd.
  • Primary Dysmenorrhea - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • KYG-0395 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etonogestrel Vaginal Ring - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PDC-31 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptidometics - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PDC-41 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Primary Dysmenorrhea - Recent Pipeline Updates
  • Primary Dysmenorrhea - Dormant Projects
  • Primary Dysmenorrhea - Product Development Milestones
    • Featured News & Press Releases
      • Dec 10, 2012: PDC Biotech Completes Phase I Study Of PDC31 For Treatment Of Preterm Labor
      • Nov 01, 2012: Merck Resolves Previously Disclosed Missouri Consumer Class Action Lawsuit Related To Vioxx
      • Nov 15, 2010: PDC Biotech announces start of Phase l trial - novel peptide for treatment of preterm labour and primary dysmenorrhea
      • Jan 05, 2010: China Aoxing Pharmaceutical Announces Successful Completion Of Phase II Clinical Study Of TJSL For The Treatment Of Primary Dysmenorrhea
      • Feb 26, 2008: Sciele Pharma, Inc. Reports Results for Fourth Quarter and Year Ended December 31, 2007
      • Oct 30, 2007: Sciele Pharma, Inc. reports revenues and earnings for the third quarter of 2007.
      • Jul 25, 2007: Sciele Pharma, Inc. Reports Revenues and Earnings for the Second Quarter 2007
      • Apr 26, 2007: Sciele Pharma, Inc. reports results for the first quarter of 2007.
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Primary Dysmenorrhea, H2 2014
  • Number of Products under Development for Primary Dysmenorrhea - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Primary Dysmenorrhea - Pipeline by Merck & Co., Inc., H2 2014
  • Primary Dysmenorrhea - Pipeline by PDC Biotech GmbH, H2 2014
  • Primary Dysmenorrhea - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Primary Dysmenorrhea Therapeutics - Recent Pipeline Updates, H2 2014
  • Primary Dysmenorrhea - Dormant Projects, H2 2014

List of Figures

  • Number of Products under Development for Primary Dysmenorrhea, H2 2014
  • Number of Products under Development for Primary Dysmenorrhea - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top